Home›Trial›NCT07478952
🔬NCT07478952Phase 1RECRUITING

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

Study Summary

The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.

Conditions
Epstein-Barr Virus
Interventions / Drugs
mRNA-1189
View on ClinicalTrials.gov ↗
Sponsor
MRNA
Moderna Inc
mRNA Therapeutics
C53/100
Study Details
Enrollment120 participants
Primary Completion—
Lead SponsorModernaTX, Inc.
Data Retrieved2026-04-11 02:55:38.209201+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.